Skip to navigationSkip to content
ALL ALONG THE PIPELINE

Psychedelic medicine companies to watch

Boxes containing magic mushrooms sit on counter at coffee and smart shop in Rotterdam
REUTERS/Jerry Lampen
You'll probably never be allowed to pick these up at a pharmacy and just take them at home.
  • Alexandra Ossola
By Alexandra Ossola

Membership editor

Published Last updated on

After decades of promising research, fading stigma, and rising need, psychedelic drugs may soon be available to treat pervasive health conditions such as PTSD, depression, and addiction.

Over the past few years, a robust business community that includes startups, investors, and even public companies sprung up in an effort to bring drugs like MDMA and psilocybin to  patients in need. The market for psychedelic medicine, valued at about $2 billion in 2019, is expected to more than triple to nearly $7 billion by 2027, according to a 2020 analysis from Data Bridge Market Research.

Because of the regulatory and administrative requirements to test, develop, and eventually administer psychedelic medicine, companies have sprung up at every stage of the pipeline. Whether today’s psychedelics startups are tomorrow’s IPO contenders will depend in part what each company is set up to do, and the point at which its founders and private investors expect an exit event.

Enrich your perspective. Embolden your work. Become a Quartz member.

Your membership supports a team of global Quartz journalists reporting on the forces shaping our world. We make sense of accelerating change and help you get ahead of it with business news for the next era, not just the next hour. Subscribe to Quartz today.

Membership includes:

こちらは英語版への登録ページです。
Quartz Japanへの登録をご希望の方はこちらから。